Gallery
- Karnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)Wedding pics: Mouni Roy marries Suraj Nambiar in South Indian ceremony73rd Republic Day Parade 2022 - In Pictures
Olympic bronze medallist Bajrang Punia has been provisionally suspended by the National An
- Laureus Award 2024 : Novak Djokovic, Aitana Bonmati win top honours at Laureus Sports Awards
- Asian Games medallist Jyothi Yarraji to train in Spain ahead of Paris Olympics
- Lione Messi said Retirement not on my mind
- Indian Wells: Alcaraz, Swiatek win titles
- African footballer chased and thrashed away in Kerala; reports
South Africa variant could reduce Covid vaccine protection: Pfizer-BioNTech Last Updated : 18 Feb 2021 05:04:47 PM IST The South African variant of Covid-19 may significantly reduce antibody protection from the Pfizer-BioNTech vaccine, as per a laboratory study, the pharmaceutical companies said. However, human trials are still to be conducted in this regard.
According to the study, published in The New England Journal of Medicine, although the results indicated a reduction in neutralisation of virus with all the South African variant spike glycoprotein mutations, the vaccine was still able to neutralise the virus.This finding is consistent with recent reports of the neutralisation of variant SARS-CoV-2 or corresponding pseudoviruses by convalescent or post-immunisation sera, the companies said in a statement on Wednesday.Pfizer and the University of Texas Medical Branch (UTMB) investigated the full set of South African variant (also known as B.1.351 lineage) spike mutations.To this aim, three genetically engineered recombinant viruses were produced. One virus had the full set of spike glycoprotein mutations found in the South African variant and the other two had subsets of these mutations.The viruses were tested against a panel of sera from 15 participants in the previously reported Phase 3 trial who had been immunised with the Pfizer-BioNTech Covid-19 vaccine.Pfizer-BioNTech said they are taking the necessary steps, making the right investments, and engaging in the appropriate conversations with regulators to be in a position to develop and seek authorisation for an updated mRNA vaccine or booster once a strain that significantly reduces the protection from the vaccine is identified, the company said.Pfizer-BioNTech are currently evaluating neutralisation of SARS-CoV-2 with the Brazilian strain spike mutations, as well as mutations from other emerging SARS-CoV-2 variants, and they continue to conduct studies to monitor the vaccine's real-world effectiveness.The pharmaceutical companies believe that the flexibility of BioNTech's proprietary mRNA vaccine platform is well suited to develop new vaccine variants, if required.IANS New York For Latest Updates Please-
Join us on
Follow us on
172.31.16.186